execution more And outlook. progress financial the this will a I today's of Cytek Cytek and to then look by I mission a will vision. and continues at to recap for Patrik results begin On how joining as today. and start the for want turn and team advance call detailed over I our call, toward with our at the call of discuss thanking Thanks, welcome, our year dedication out XXXX. again third close we everyone, Paul, and quarter to their our
our net the Our We globe, EBITDA, income and results demonstrate our broader sales margins, this our the in revenue effectively diversifying quarter achieved growing on operate challenging environment. across base our success our a and further continued gross across improvement and adjusted strategy. efforts business while all efficiently to executing of macro
factors macro proud ability industry, Although the achievements our to demonstrated evolving XXXX to beyond. impact adapt environment, of the to continue confident the I'm I'm broader and and the of remainder and for team's
at Cytek provide software apart services. to solution the we as consisting end-to-end As landscape, we of an our customers continues instruments, with industry stand look the reagents, field in application and
Our we unique solutions demonstrated sector, leader our us customers. and value portfolio provide are the proud positions of in we to a as of the comprehensive
further beyond This led which a of stream comprehensive products year, sale highlighted and services, to suite of we revenue has instruments. the our have of consistently our diversification
As said to revenue which we instruments, suite to demand, contribute orders to enterprise we have previously, expect continue of growth. reagents see beyond sales our original future considerably and our our solid
field. installed that robust the I'm base pleased to of continue growth say achieve our instruments in to
of more our cell placed widespread being of strategy penetration of in moment across instruments first growth across achieve of how to expanding countries. adoption take use analysis globe we XX want to total entry-level to our XXXX, placements Along strategy those cell introduced gained speak XXX than quarter, our demonstrated results instruments, global lines, third range our in has the our with for a our base from to core X,XXX Since to users I company. systems have the reflect the During as bringing users the installed these users. to high-sensitivity Furthermore, QX. end analysis
and X%, the last of for our the and revenue, only company's XX% APAC EMEA accounted the U.S. respectively. while XX% year's quarter, third In regions sales within were
as Cytek's with to in overall of XX% of I our expand our of past now representing is sales. our region efforts, Clearly, expansion revenue. XX this globally. overall our look this to XX% sales strategy and yielding grew points, our our presence Further, percent Now sales continued results, APAC to EMEA line for account a quarter, in progress total, grew by forward
achieved to In the the addition our to whole this revenue, operating in instrument XXXX conditions I overall successful continuing and again face grow challenging base our macro to of throughout efforts team's in acknowledge strong and and results. want of quarter
that, quarter. of margins XX%, our expanding income EBITDA XX% over from and gross see other reagent prior and as to continue in margin as on to confident consistently strong business last achieve adjusted gross high-margin over were margins. I'm both grew we of offerings, adjusted our quarter, as $X.X over net million, scale importantly, And This our well stable ability reported And we and increased to top the year. third our significantly year's in continue
by diligent not in I Cytek, It ahead. this the that are our move on us team field efforts believe want throughout apart of to effective positions entire and us further focus efficient for we these sets and the as the reiterate, result is accident. of operations achievements I success
a manage For previously, chain operations of the leveraging chain pressures. our in mitigation focused continue demonstrated environment to through confident intentional pressures our manage through potential strategy Cytek and the remain concerns. inflationary a this past have is our macro team be discussed from to maintain we In all, we able and the challenges. to by despite provides ability withstand execution, team's buffer insulate to succeed our disruption global I supply as in on continue further ongoing order Furthermore, and inventory workforce example, to to to supply
and April, in appointment X already results Chief Among an now to our We've months has of announced more Officer European of Todd the has the many been Garland developed for At Commercial come. our as execution of and, his only Todd strategy. we our the success. Todd recent end role, company's into focus, plan areas demonstrated sales instrumental
Chris full our we announced last the as recently, of Group. Cytek, single-use customers. was Thermo Services Williams Cytek's solution More support and And to and Operations and Operating was our a Manager at he to VP to for Officer and automation, VP Engineering, global to lead as Thermo technologies up provider our execute scale Technology, of and General strategy Chris to General before just that, joining equipment Innovations our week, for the operations for Fisher both Fisher’s appointment VP Scientific. the and Pharma Chief the Prior mission Manager capability bioprocess
a is our the ability we on company time Chris that are Cytek. at our He I at growth to components Around focus trajectory this growth process to is us large this. lines, requires on target ensuring want automation to are our take critical with important for we as to and that efficiently moment welcome conducted improvements an of team joins the a those scale, and as scale. markets
and our help We are us most person we organization. right forward opportunities, is make confident our the what of to lead are for that and excited for growth Chris the comes next
continue we the grow now reagents XXX instruments, technology offerings quarter. our of the our as of has and and base the been As end of services, to by peer-reviewed publications validated
in community. were and our scientific mentioning speaks to our proud peer-reviewed there which this validates alone, momentum platform publications very offerings quarter the of the Cytek. accomplishment, I'm use This XXX the of of
how Of to vaccine second researchers promise immunization Medical the targets. for Institute published gut immune researchers a distinct functions paper, system. paper process how slower School the on from major difficult HIV in T one in by In a nature showed bacteria at note, cells holds showed direct NYU Scripps adaptive Research adopt
FSP that rapidly provides research our we platform and growing, pleased this into is are Microbiome promising area. insights
real-world proven As see, demonstrate and of these community. technology you the can scientific many papers the to applications others services our and
In throughout all, has made team pleased I'm our once progress with again, quarter this and XXXX. the
new and provide these on forward providing customers. forward continuing applications, we to cadence complete a novel our look the continue platform scientific we a analysis customers focused discovery they remain progress. solution clinical FSP products bounds to We to to of As as push push cell to and of our deeply
now our more will call over details turn for I Patrik the that, to around financials. With
